Analysts expect that Heron Therapeutics (NASDAQ:HRTX) will post earnings of ($0.82) per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Heron Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.07) and the highest estimate coming in at ($0.57). Heron Therapeutics reported earnings of ($1.00) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 18%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, May 9th.
On average, analysts expect that Heron Therapeutics will report full-year earnings of ($2.48) per share for the current financial year, with EPS estimates ranging from ($3.69) to ($1.83). For the next fiscal year, analysts expect that the company will post earnings of ($0.71) per share, with EPS estimates ranging from ($1.64) to $0.87. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.29). The business had revenue of $10.05 million for the quarter, compared to analyst estimates of $9.00 million. Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%.
A number of equities research analysts have recently issued reports on HRTX shares. BidaskClub raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Leerink Swann started coverage on shares of Heron Therapeutics in a report on Tuesday, January 2nd. They issued an “outperform” rating and a $22.00 target price on the stock. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Friday, January 5th. Finally, Zacks Investment Research cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $35.92.
In related news, Director Kevin C. Tang purchased 192,308 shares of the stock in a transaction on Thursday, March 29th. The shares were purchased at an average cost of $26.00 per share, with a total value of $5,000,008.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Barry D. Quart sold 100,000 shares of the stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $29.75, for a total transaction of $2,975,000.00. Following the completion of the transaction, the chief executive officer now directly owns 167,993 shares in the company, valued at $4,997,791.75. The disclosure for this sale can be found here. Over the last three months, insiders sold 218,000 shares of company stock worth $5,990,000. Insiders own 19.93% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Swiss National Bank raised its holdings in Heron Therapeutics by 25.5% in the 4th quarter. Swiss National Bank now owns 98,500 shares of the biotechnology company’s stock valued at $1,783,000 after acquiring an additional 20,000 shares during the period. Ellington Management Group LLC bought a new position in Heron Therapeutics in the 4th quarter valued at about $195,000. Deltec Asset Management LLC bought a new position in Heron Therapeutics in the 4th quarter valued at about $2,118,000. Teacher Retirement System of Texas bought a new position in Heron Therapeutics in the 4th quarter valued at about $272,000. Finally, Claraphi Advisory Network LLC bought a new position in Heron Therapeutics in the 4th quarter valued at about $335,000. 97.41% of the stock is currently owned by hedge funds and other institutional investors.
Shares of HRTX stock traded down $0.20 on Friday, reaching $30.70. The stock had a trading volume of 917,871 shares, compared to its average volume of 1,278,362. The stock has a market cap of $2,132.40, a price-to-earnings ratio of 8.46 and a beta of 1.88. Heron Therapeutics has a 12 month low of $12.70 and a 12 month high of $32.70.
TRADEMARK VIOLATION NOTICE: “Heron Therapeutics (HRTX) Expected to Announce Earnings of -$0.82 Per Share” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/18/heron-therapeutics-hrtx-expected-to-announce-earnings-of-0-82-per-share.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.